inflammation
-
Third Harmonic’s $183M stock market debut stands out in a sea of stalled IPOs
Third Harmonic Bio’s IPO raised $183.3 million for clinical development of an inflammation drug licensed from Novartis. The biotech was able to find enough investor interest to increase the deal size, offering 1.9 million more shares than initially planned.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Third Harmonic pushes IPO window open with inflammation drug from Novartis
Third Harmonic Bio, which emerged from stealth early this year with a lead drug from Novartis and a $105 million round of funding, has not yet set any financial terms for its planned IPO. But the biotech plans to use the IPO cash for early and mid-stage clinical tests of its small molecule in multiple inflammatory indications.
-
Daily, Artificial Intelligence, BioPharma
With 3 inflammation drugs on path to the clinic, Ventus Therapeutics adds $140M
Ventus Therapeutics’ lead programs address pathways associated with inflammation. Led by CEO Marcelo Bigal, the biotech discovers its drugs using computational analysis to understand the structure of proteins and find small molecules that can hit these “undruggable” targets.
-
Pfizer: $6.7B Arena buyout complements rather than replaces JAK drugs
Sales of blockbuster Pfizer drug Xeljanz are under pressure from a stronger safety warning placed across that drug’s entire class. In acquiring Arena Pharmaceuticals for $6.7 billion, Pfizer gets a lead compound with a different and potentially safer approach to treating inflammatory conditions.
-
Exo Therapeutics adds $78M as cancer, inflammation drugs march toward clinic
Biotech startup Exo Therapeutics aims to overcome the challenges of drugging proteins by targeting exosites, locations that modulate enzyme activity. The company has four small molecule drug candidates for cancer and inflammation, and the company plans to use the $78 million in new financing to advance them toward human testing.
-
Better late than never? Eczema drug now approved, Incyte says warning unwarranted
Atopic dermatitis patients now have a new therapeutic option that comes as a topical cream. The FDA approved Incyte’s drug, Opzelura, as a treatment for the inflammatory skin condition, but the regulatory nod comes with a black box warning on the label that broadly covers the entire class of JAK inhibitors.
-
Roche antibody gets FDA authorization for treating hospitalized Covid-19 patients
The FDA has granted emergency use authorization to a Roche antibody as a treatment for hyperinflammation in patients hospitalized with severe Covid-19. The drug, Actemra, is an anti-inflammatory medication already approved for treating rheumatoid arthritis.
-
Eying eczema, Amgen pays $400M to co-develop Phase 3-ready Kyowa Kirin drug
Amgen is paying Kyowa Kirin $400 million to share in the development of a drug that could offer a new approach to treating atopic dermatitis, a form of eczema. The deal comes months after Japan-based Kyowa Kirin reported positive preliminary Phase 2 data for its antibody.
-
Navigating Healthcare’s Data Revolution: Priorities, Opportunities, and Challenges for Health Systems
Arcadia recently partnered with HIMSS Market Insights to survey executives, IT, technology, and clinical leaders. Here’s what we found.
-
Ventus Therapeutics tacks on $100M to take on ‘undruggable’ disease targets
RA Capital led Ventus Therapeutics’ Series B financing, which the startup will use to develop its pipeline of medicines for “undruggable” disease targets. CEO Marcelo Bigal said the cash also gives Ventus the flexibility to consider an IPO.
-
Biotech Vividion lands $135M in crossover cash, paving a path to the public markets
Vividion Therapeutics has technology that enables it to develop drugs for “undruggable” disease targets. The Series C financing is a crossover round, an indication a biotech is preparing for an IPO.
-
Eli Lilly bolsters neuro, immunology pipeline via multi-drug alliance with Rigel
Eli Lilly is paying $125 million up front to team up with Rigel Pharmaceuticals on drugs that block a signaling protein involved in inflammation. With the alliance, Lilly joins Sanofi and Denali Therapeutics in the pursuit of drugs that block this protein.
-
BMS, Celgene tout synergies in $74B mega-deal, but Revlimid’s winter is coming
In a call to following news of the deal, executives pointed to near-term launch opportunities and pipelines, but some analysts expressed concern about the loss of patent protection for Revlimid and Opdivo.
-
Top Story, Devices & Diagnostics, Diagnostics
Kypha, startup looking to monitor inflammation quickly and accurately, raises $2.1M
Managing inflammation is critical for many conditions – Lupus being a major one.